{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:52:35Z","timestamp":1791312755907,"version":"4.3.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"31","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.vaccine.2010.05.023","type":"journal-article","created":{"date-parts":[[2010,5,27]],"date-time":"2010-05-27T09:13:32Z","timestamp":1274951612000},"page":"4997-5004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Single-shot immunization with recombinant adenovirus encoding vaccinia virus glycoprotein A27L is protective against a virulent respiratory poxvirus infection"],"prefix":"10.1016","volume":"28","author":[{"given":"Rajeev","family":"Rudraraju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair J.","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2010.05.023_bib1","series-title":"The global eradication of smallpox. Final report of the global commission for the certification of smallpox eradication","year":"1980"},{"issue":"July (2)","key":"10.1016\/j.vaccine.2010.05.023_bib2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1086\/375825","article-title":"Smallpox vaccination: a review. Part II. Adverse events","volume":"37","author":"Fulginiti","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"December (21)","key":"10.1016\/j.vaccine.2010.05.023_bib3","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1001\/jama.294.21.2734","article-title":"Adverse events associated with smallpox vaccination in the United States, January\u2013October 2003","volume":"294","author":"Casey","year":"2005","journal-title":"JAMA"},{"issue":"June (3)","key":"10.1016\/j.vaccine.2010.05.023_bib4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.coi.2009.04.004","article-title":"The immunology of smallpox vaccines","volume":"21","author":"Kennedy","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2010.05.023_bib5","unstructured":"US Food and Drug Administration. http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/QuestionsaboutVaccines\/ucm078041.htm. February 23, 2010."},{"issue":"July\u2013August (4)","key":"10.1016\/j.vaccine.2010.05.023_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/rmv.571","article-title":"New generation smallpox vaccines: a review of preclinical and clinical data","volume":"18","author":"Artenstein","year":"2008","journal-title":"Rev Med Virol"},{"issue":"June (2)","key":"10.1016\/j.vaccine.2010.05.023_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1006\/viro.1994.1288","article-title":"Analysis of the complete genome of smallpox variola major virus strain Bangladesh-1975","volume":"201","author":"Massung","year":"1994","journal-title":"Virology"},{"issue":"February (1)","key":"10.1016\/j.vaccine.2010.05.023_bib8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0042-6822(02)00038-7","article-title":"Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates","volume":"306","author":"Hooper","year":"2003","journal-title":"Virology"},{"issue":"February (1)","key":"10.1016\/j.vaccine.2010.05.023_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.virol.2007.09.029","article-title":"Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens","volume":"371","author":"Sakhatskyy","year":"2008","journal-title":"Virology"},{"issue":"March (5)","key":"10.1016\/j.vaccine.2010.05.023_bib10","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1128\/JVI.80.5.2127-2140.2006","article-title":"Vaccinia virus proteome: identification of proteins in vaccinia virus intracellular mature virion particles","volume":"80","author":"Chung","year":"2006","journal-title":"J Virol"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2010.05.023_bib11","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1128\/jvi.68.10.6401-6410.1994","article-title":"Conditional lethal expression of the vaccinia virus L1R myristylated protein reveals a role in virion assembly","volume":"68","author":"Ravanello","year":"1994","journal-title":"J Virol"},{"issue":"January (Pt (1))","key":"10.1016\/j.vaccine.2010.05.023_bib12","first-page":"47","article-title":"The vaccinia virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles","volume":"81","author":"Sanderson","year":"2000","journal-title":"J Gen Virol"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2010.05.023_bib13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1128\/JVI.75.1.303-310.2001","article-title":"The vaccinia virus A33R protein provides a chaperone function for viral membrane localization and tyrosine phosphorylation of the A36R protein","volume":"75","author":"Wolffe","year":"2001","journal-title":"J Virol"},{"issue":"May (1)","key":"10.1016\/j.vaccine.2010.05.023_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1006\/viro.2000.0260","article-title":"The vaccinia virus A36R protein is a type Ib membrane protein present on intracellular but not extracellular enveloped virus particles","volume":"271","author":"van Eijl","year":"2000","journal-title":"Virology"},{"issue":"June (2)","key":"10.1016\/j.vaccine.2010.05.023_bib15","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1006\/viro.1993.1302","article-title":"The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence","volume":"194","author":"Engelstad","year":"1993","journal-title":"Virology"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2010.05.023_bib16","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1128\/jvi.71.5.3904-3915.1997","article-title":"The A34R glycoprotein gene is required for induction of specialized actin-containing microvilli and efficient cell-to-cell transmission of vaccinia virus","volume":"71","author":"Wolffe","year":"1997","journal-title":"J Virol"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2010.05.023_bib17","doi-asserted-by":"crossref","first-page":"4732","DOI":"10.1128\/jvi.67.8.4732-4741.1993","article-title":"Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination","volume":"67","author":"Wolffe","year":"1993","journal-title":"J Virol"},{"issue":"May (9)","key":"10.1016\/j.vaccine.2010.05.023_bib18","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1128\/JVI.78.9.4433-4443.2004","article-title":"Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox","volume":"78","author":"Hooper","year":"2004","journal-title":"J Virol"},{"issue":"November (2)","key":"10.1016\/j.vaccine.2010.05.023_bib19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.virol.2006.07.017","article-title":"Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen","volume":"355","author":"Sakhatskyy","year":"2006","journal-title":"Virology"},{"issue":"September (25\u201326)","key":"10.1016\/j.vaccine.2010.05.023_bib20","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1016\/j.vaccine.2004.02.034","article-title":"Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB\/c mice from a lethal intranasal poxvirus challenge","volume":"22","author":"Pulford","year":"2004","journal-title":"Vaccine"},{"issue":"October (19)","key":"10.1016\/j.vaccine.2010.05.023_bib21","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1128\/JVI.78.19.10230-10237.2004","article-title":"Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions","volume":"78","author":"Fogg","year":"2004","journal-title":"J Virol"},{"issue":"July (14)","key":"10.1016\/j.vaccine.2010.05.023_bib22","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.1128\/JVI.00353-08","article-title":"Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice","volume":"82","author":"Kaufman","year":"2008","journal-title":"J Virol"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2010.05.023_bib23","doi-asserted-by":"crossref","first-page":"5631","DOI":"10.1128\/jvi.65.10.5631-5635.1991","article-title":"The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals","volume":"65","author":"Lai","year":"1991","journal-title":"J Virol"},{"issue":"April (7)","key":"10.1016\/j.vaccine.2010.05.023_bib24","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1128\/JVI.01854-07","article-title":"Vaccination of BALB\/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge","volume":"82","author":"Berhanu","year":"2008","journal-title":"J Virol"},{"issue":"August (4)","key":"10.1016\/j.vaccine.2010.05.023_bib25","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.4049\/jimmunol.177.4.2552","article-title":"Subunit recombinant vaccine protects against monkeypox","volume":"177","author":"Heraud","year":"2006","journal-title":"J Immunol"},{"issue":"December (2)","key":"10.1016\/j.vaccine.2010.05.023_bib26","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.vaccine.2009.09.133","article-title":"Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates","volume":"28","author":"Hooper","year":"2009","journal-title":"Vaccine"},{"issue":"September (18)","key":"10.1016\/j.vaccine.2010.05.023_bib27","doi-asserted-by":"crossref","first-page":"11724","DOI":"10.1128\/JVI.79.18.11724-11733.2005","article-title":"Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice","volume":"79","author":"Davies","year":"2005","journal-title":"J Virol"},{"issue":"October","key":"10.1016\/j.vaccine.2010.05.023_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-065X.1999.tb01341.x","article-title":"Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity","volume":"171","author":"Ramsay","year":"1999","journal-title":"Immunol Rev"},{"issue":"June (2)","key":"10.1016\/j.vaccine.2010.05.023_bib29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ymeth.2003.11.006","article-title":"Utilization of adenovirus vectors for multiple gene transfer applications","volume":"33","author":"Amalfitano","year":"2004","journal-title":"Methods"},{"issue":"December (51)","key":"10.1016\/j.vaccine.2010.05.023_bib30","doi-asserted-by":"crossref","first-page":"51872","DOI":"10.1074\/jbc.M310038200","article-title":"Two distinct transport motifs in the adenovirus E3\/10.4\u201314.5 proteins act in concert to down-modulate apoptosis receptors and the epidermal growth factor receptor","volume":"278","author":"Hilgendorf","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2010.05.023_bib31","series-title":"Vaccines, vaccination and the immune response","author":"Ada","year":"1997"},{"issue":"December (3)","key":"10.1016\/j.vaccine.2010.05.023_bib32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/35105075","article-title":"Strategies for designing and optimizing new generation vaccines","volume":"1","author":"Berzofsky","year":"2001","journal-title":"Nat Rev Immunol"},{"issue":"August (4)","key":"10.1016\/j.vaccine.2010.05.023_bib33","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/icb.1997.56","article-title":"DNA immunization","volume":"75","author":"Ramsay","year":"1997","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2010.05.023_bib34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1479-0556-6-5","article-title":"Organ distribution of transgene expression following intranasal mucosal delivery of recombinant replication-defective adenovirus gene transfer vector","volume":"6","author":"Damjanovic","year":"2008","journal-title":"Genet Vaccines Ther"},{"key":"10.1016\/j.vaccine.2010.05.023_bib35","first-page":"493","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Hygiene"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2010.05.023_bib36","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1592","article-title":"Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major","volume":"13","author":"Darrah","year":"2007","journal-title":"Nat Med"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2010.05.023_bib37","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri2274","article-title":"T-cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"February (10)","key":"10.1016\/j.vaccine.2010.05.023_bib38","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.vaccine.2006.11.017","article-title":"Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge","volume":"25","author":"Hooper","year":"2007","journal-title":"Vaccine"},{"issue":"February (1)","key":"10.1016\/j.vaccine.2010.05.023_bib39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/viro.1998.9516","article-title":"Neutralizing and protective antibodies directed against vaccinia virus envelope antigens","volume":"254","author":"Galmiche","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2010.05.023_bib40","article-title":"Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge","author":"He","year":"2009","journal-title":"Vaccine"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2010.05.023_bib41","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1128\/jvi.66.1.386-398.1992","article-title":"Identification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans","volume":"66","author":"Demkowicz","year":"1992","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10006997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10006997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:19:31Z","timestamp":1759400371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10006997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":41,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S0264410X10006997"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.05.023","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-shot immunization with recombinant adenovirus encoding vaccinia virus glycoprotein A27L is protective against a virulent respiratory poxvirus infection","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}